Premium
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study
Author(s) -
Nordström Lena,
Sernbo Sandra,
Eden Patrik,
Grønbæk Kirsten,
Kolstad Arne,
Räty Riikka,
Karjalainen MarjaLiisa,
Geisler Christian,
Ralfkiær Elisabeth,
Sundström Christer,
Laurell Anna,
Delabie Jan,
Ehinger Mats,
Jerkeman Mats,
Ek Sara
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12854
Subject(s) - mantle cell lymphoma , international prognostic index , medicine , rituximab , cyclin d1 , oncology , cytarabine , lymphoma , etoposide , transplantation , cancer research , chemotherapy , cell cycle , cancer
Summary Mantle cell lymphoma ( MCL ) is an aggressive B cell lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem cell transplantation, such as the Nordic MCL 2/3 protocols. In 2008, a MCL international prognostic index ( MIPI ) was created to enable stratification of the clinical diverse MCL patients into three risk groups. So far, use of the MIPI in clinical routine has been limited, as it has been shown that it inadequately separates low and intermediate risk group patients. To improve outcome and minimize treatment‐related morbidity, additional parameters need to be evaluated to enable risk‐adapted treatment selection. We have investigated the individual prognostic role of the MIPI and molecular markers including SOX 11, TP 53 (p53), MKI 67 (Ki‐67) and CCND1 (cyclin D1). Furthermore, we explored the possibility of creating an improved prognostic tool by combining the MIPI with information on molecular markers. SOX 11 was shown to significantly add prognostic information to the MIPI , but in multivariate analysis TP 53 was the only significant independent molecular marker. Based on these findings, we propose that TP 53 and SOX 11 should routinely be assessed and that a combined TP 53/ MIPI score may be used to guide treatment decisions.